109 related articles for article (PubMed ID: 12724216)
1. The development of CpG island methylation biomarkers using restriction landmark genomic scanning.
Smiraglia DJ; Plass C
Ann N Y Acad Sci; 2003 Mar; 983():110-9. PubMed ID: 12724216
[TBL] [Abstract][Full Text] [Related]
2. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC).
Smiraglia DJ; Smith LT; Lang JC; Rush LJ; Dai Z; Schuller DE; Plass C
J Med Genet; 2003 Jan; 40(1):25-33. PubMed ID: 12525538
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.
Basu B; Chakraborty J; Chandra A; Katarkar A; Baldevbhai JRK; Dhar Chowdhury D; Ray JG; Chaudhuri K; Chatterjee R
Clin Epigenetics; 2017; 9():13. PubMed ID: 28174608
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning.
Wang SS; Smiraglia DJ; Wu YZ; Ghosh S; Rader JS; Cho KR; Bonfiglio TA; Nayar R; Plass C; Sherman ME
Cancer Res; 2008 Apr; 68(7):2489-97. PubMed ID: 18381458
[TBL] [Abstract][Full Text] [Related]
5. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies.
Smiraglia DJ; Rush LJ; Frühwald MC; Dai Z; Held WA; Costello JF; Lang JC; Eng C; Li B; Wright FA; Caligiuri MA; Plass C
Hum Mol Genet; 2001 Jun; 10(13):1413-9. PubMed ID: 11440994
[TBL] [Abstract][Full Text] [Related]
6. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
[TBL] [Abstract][Full Text] [Related]
7. Gene promoter-associated CpG island hypermethylation in squamous cell carcinoma of the tongue.
Bhat S; Kabekkodu SP; Jayaprakash C; Radhakrishnan R; Ray S; Satyamoorthy K
Virchows Arch; 2017 Apr; 470(4):445-454. PubMed ID: 28255813
[TBL] [Abstract][Full Text] [Related]
8. Restriction landmark genome scanning.
Costello JF; Smiraglia DJ; Plass C
Methods; 2002 Jun; 27(2):144-9. PubMed ID: 12095273
[TBL] [Abstract][Full Text] [Related]
9. Predicting aberrant CpG island methylation.
Feltus FA; Lee EK; Costello JF; Plass C; Vertino PM
Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12253-8. PubMed ID: 14519846
[TBL] [Abstract][Full Text] [Related]
10. CpG island hypermethylation profiling of lung cancer using restriction landmark genomic scanning (RLGS) analysis.
Park J; Brena RM; Gruidl M; Zhou J; Huang T; Plass C; Tockman MS
Cancer Biomark; 2005; 1(2-3):193-200. PubMed ID: 17192040
[TBL] [Abstract][Full Text] [Related]
11. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay.
Rauch T; Wang Z; Zhang X; Zhong X; Wu X; Lau SK; Kernstine KH; Riggs AD; Pfeifer GP
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5527-32. PubMed ID: 17369352
[TBL] [Abstract][Full Text] [Related]
12. Infrequent occurrence of age-dependent changes in CpG island methylation as detected by restriction landmark genome scanning.
Tra J; Kondo T; Lu Q; Kuick R; Hanash S; Richardson B
Mech Ageing Dev; 2002 Sep; 123(11):1487-503. PubMed ID: 12425956
[TBL] [Abstract][Full Text] [Related]
13. The study of aberrant methylation in cancer via restriction landmark genomic scanning.
Smiraglia DJ; Plass C
Oncogene; 2002 Aug; 21(35):5414-26. PubMed ID: 12154404
[TBL] [Abstract][Full Text] [Related]
14. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
[TBL] [Abstract][Full Text] [Related]
15. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.
Nakayama M; Gonzalgo ML; Yegnasubramanian S; Lin X; De Marzo AM; Nelson WG
J Cell Biochem; 2004 Feb; 91(3):540-52. PubMed ID: 14755684
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation of collagen α2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Imai A; Endo S; Hakamada K; Mineta H
Cancer Biomark; 2011-2012; 10(3-4):135-44. PubMed ID: 22674299
[TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
18. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation.
Bastian PJ; Yegnasubramanian S; Palapattu GS; Rogers CG; Lin X; De Marzo AM; Nelson WG
Eur Urol; 2004 Dec; 46(6):698-708. PubMed ID: 15548435
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
Gebhard C; Schwarzfischer L; Pham TH; Schilling E; Klug M; Andreesen R; Rehli M
Cancer Res; 2006 Jun; 66(12):6118-28. PubMed ID: 16778185
[TBL] [Abstract][Full Text] [Related]
20. Identification of DNA methylation in 3' genomic regions that are associated with upregulation of gene expression in colorectal cancer.
Smith JF; Mahmood S; Song F; Morrow A; Smiraglia D; Zhang X; Rajput A; Higgins MJ; Krumm A; Petrelli NJ; Costello JF; Nagase H; Plass C; Held WA
Epigenetics; 2007 Sep; 2(3):161-72. PubMed ID: 17965620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
